Abstract:Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease (PD), which is the leading neurodegenerative movement disorder characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). However, whether LRRK2 mutations cause PD and degeneration of DA neurons a toxic gain-of-function or a loss-of-function mechanism is unresolved and has pivotal implications for LRRK2-based PD therapies. In this study, we investigate whether LRRK2 and its functional homologue LRRK1 play an essential, intrinsic role in DA neuron survival through the development of DA neuron-specific conditional double knockout (cDKO) mice. We first generated and characterized floxed and mice and then confirmed that germline deletions of the floxed and alleles result in null mutations, as evidenced by the absence of and mRNA and protein in the respective homozygous deleted mutant mice. We further examined the specificity of Cre-mediated recombination driven by the - ( ) knockin (KI) allele using a GFP reporter line and confirmed that -mediated recombination is restricted to DA neurons in the SNpc. Crossing these validated floxed and mice with KI mice, we then generated DA neuron-restricted cDKO mice and further showed that levels of LRRK1 and LRRK2 are reduced in dissected ventral midbrains of cDKO mice. While DA neuron-restricted cDKO mice of both sexes exhibit normal mortality and body weight, they develop age-dependent loss of DA neurons in the SNpc, as demonstrated by the progressive reduction of DA neurons in the SNpc of cDKO mice at the ages of 20 and 24 months but the unaffected number of DA neurons at the age of 15 months. Moreover, DA neurodegeneration is accompanied with increases of apoptosis and elevated microgliosis in the SNpc as well as decreases of DA terminals in the striatum, and is preceded by impaired motor coordination. Taken together, these findings provide the unequivocal evidence for the importance of LRRK in DA neurons and raise the possibility that LRRK2 mutations may impair its protection of DA neurons, leading to DA neurodegeneration in PD.

LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies

LRRK2-mediated microglial activation via NFATc2: a novel mechanism of neurotoxic inflammation in synucleinopathies

Microglial LRRK2-mediated NFATc1 attenuates α-synuclein immunotoxicity in association with CX3CR1-induced migration and the lysosome-initiated degradation

LRRK2 kinase activity restricts NRF2-dependent mitochondrial protection in microglia

Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells

LRRK2-NFATc2 Pathway Associated with Neuroinflammation May Be a Potential Therapeutic Target for Parkinson’s Disease

LRRK2 Kinase Activity Induces Mitochondrial Fission in Microglia via Drp1 and Modulates Neuroinflammation

Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant Α-Synuclein

The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons

LRRK2-mutant microglia trigger dopaminergic neurodegeneration when activated by neuromelanin

Knockout of the LRRK2-counteracting RAB phosphatase PPM1H disrupts axonal autophagy and exacerbates alpha-synuclein aggregation

LRRK2 suppresses lysosome degradative activity in macrophages and microglia through MiT-TFE transcription factor inhibition

LRRK2 regulates production of reactive oxygen species in cell and animal models of Parkinson's disease

Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease

Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model

Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons

Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

LRRK2 aggravates kidney injury through promoting MFN2 degradation and abnormal mitochondrial integrity

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons